ArticleScientific reports2025
Breath-based stratification of asthma severity using the MISTRAL platform with integrated H
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exhaled breath analysis offers a painless window into airway inflammation, yet its clinical adoption is limited by a shortage of robust biomarkers. Hydrogen sulfide ([Formula: see text]) has been detected in biological fluids, but its diagnostic value across asthma severities is not well established. In this study, we integrated an electrochemical [Formula: see text] sensor with a detection limit of 1 ppb into the MISTRAL platform. We evaluated exhaled [Formula: see text] in a prospective cohort of 28 adult asthmatic patients. Mean exhaled [Formula: see text] concentrations were significantly higher in individuals with mild-to-moderate asthma ([Formula: see text]) than in those with severe asthma ([Formula: see text]; one‑tailed t‑test [Formula: see text], [Formula: see text]). In early-stage disease, [Formula: see text] levels negatively correlated with maximal expiratory flow MEF[Formula: see text], with a similar trend for MEF[Formula: see text], whereas in severe asthma, positive but not fully statistically significant correlations emerged with FEV[Formula: see text]/FVC ratio, and vital capacity VC. These findings reveal a biphasic pattern: elevated [Formula: see text] may signify a compensatory antioxidant response that collapses as damage in the medium-to-peripheral airways progresses. The plug-and-play MISTRAL platform thus enables real-time, point-of-care assessment of exhaled [Formula: see text] as a promising, and complementary biomarker to FeNO and blood eosinophil count, offering a rapid, non-invasive indicator of disease control, treatment responsiveness, and exacerbation risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.